hVIVOOPORF +27.29%43 EV-to-FCF is -3.11 as of Jun. 26, 2026. GuruFocus rates OPORF with a GF Score™ of 43/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, hVIVO ranks worse than 1020407.14% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, hVIVO's Enterprise Value is $66.35 Mil.
hVIVO's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.36 Mil. Therefore, hVIVO's EV-to-FCF for today is -3.11.
The historical rank and industry rank for hVIVO's EV-to-FCF or its related term are showing as below:
OPORF'
s EV-to-FCF Range Over the Past 10 Years
Min: -61.26 Med: 0.4 Max: 5446.04
Current: -3.44
During the past 13 years, the highest EV-to-FCF of hVIVO was 5446.04. The lowest was -61.26. And the median was 0.40.
OPORF's EV-to-FCF is ranked worse than 100% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.585
vs OPORF: -3.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-26), hVIVO's stock price is $0.1096.
hVIVO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.011. Therefore, hVIVO's PE Ratio (TTM) for today is At Loss.
hVIVO (OTCPK:OPORF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
hVIVO's share price for today is $0.1096.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. hVIVO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
hVIVO EV-to-FCF Related Terms
hVIVO EV-to-FCF Historical Data
* Premium members only.
The historical data trend for hVIVO's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, hVIVO's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where hVIVO's EV-to-FCF falls into.
hVIVO's current Enterprise Value is $66.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. hVIVO's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
hVIVO (OPORF) has a EV-to-FCF of -3.11 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on hVIVO and its competitors. According to the industry distribution chart, hVIVO ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry.
Is hVIVO's EV-to-FCF too high?
hVIVO's current EV-to-FCF is -3.11. Based on the distribution chart, hVIVO ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, hVIVO has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #999999 out of 98 companies for EV-to-FCF. This places hVIVO in the lower half of its industry. The industry median EV-to-FCF is 22.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.59, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on hVIVO and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. hVIVO's current EV-to-FCF is -3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.11 — trading 81.7% below its estimated fair value. The current EV-to-FCF is -3.11. hVIVO's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For hVIVO (OPORF), the current EV-to-FCF is -3.11 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60.
GuruFocus considers hVIVO to be Possible Value Trap.
Key valuation signals for OPORF:
EV-to-FCF: -3.11
GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
43GF Score
Get the complete analysis for OPORF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
